Table 1.

Pharmacokinetic parameters (geometric means (gSD), [range]) of cerivastatin and its metabolites M-1 and M-23 following a single oral dose of 0.2 mg given to eight liver transplant recipients on individual tacrolimus treatment compared with previous data obtained in healthy subjects [8, 9].

	AUC (µg l−1 h)	Cmax (µg l−1)	t½ (h)	Aeur# [%]
Cerivastatin
Liver transplant patients	19.8 (1.54)	3.2 (1.48)	2.8 (1.23)	n.m.##
(n = 8)	[11.7, 43.8]	[2.3, 6.7]	[1.9, 3.5]
Healthy male subjects	15.3 (1.33)	2.4 (1.34)	3.2 (1.22)	n.m.##
(n = 29) [9]
Metabolite M-1
Liver transplant patients	2.2 (1.55)	0.24 (1.64)	3.6 (2.18)	2.26 ± 0.99
(n = 5)	[1.12, 3.40]	[0.13, 0.58]	[1.5, 11.9]	[0.57, 4.04]
Healthy male subjects	1.2 (1.06)	0.16 (1.38)	3.4 (1.35)	2.33 ± 1.44
(n = 12) [8]
Metabolite M-23 data
Liver transplant patients	6.6 (1.43)	0.63 (1.32)	4.9 (1.92)	7.59 ± 2.37
(n = 8)	[4.1, 11.1]	[0.40, 0.91]	[1.8, 14.0]	[3.95, 10.1]
Healthy male subjects	3.2 (1.38)	0.32 (1.22)	5.1 (1.60)	7.51 ± 3.50
(n = 12) [8]

^#arithmetic means ± s.d.

^##n.m. = not measured (as cerivastatin is not excreted unchanged in urine).